The aim of Andes Biotechnologies is to carry out research and development of new anticancer therapies based on the inactivation of novel non-coding mitochondrial RNA targets through anti-sense and/or RNAi technology. Andes has a portfolio of 9 patent applications in key markets around the world, covering the diagnostic and therapeutic uses of non-coding mitochondrial RNA oligonucleotides which have the potential of selectively eliminating tumor cells without harming normal cells in many Cancer types. The company has a management team with extensive experience in drug development and biotechnology research, which has successfully developed, patented and registered products currently marketed in the U.S. and Europe.
